- Stocks
- Pharma & Healthcare
- SAMSRITA LABS
SAMSRITA LABS share price
NSE: SAMSRITAPharma & HealthcareDiagnostics & Research
SAMSRITA LABS at a glance
With a market capitalisation of ₹28 Cr, it ranks 3413th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
Its return on equity was −69.4% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹347 Cr (+8.7% year on year) and net profit ₹22 Cr (+7.0%), on a consolidated basis. Promoters held 25.44% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹28 CrRank 3413 on NSE
- Price to book
- 3.07×FY26
- EPS (TTM)
- ₹53.34to Q1 FY27
- ROE
- −69.4%FY26
- ROCE
- −73.3%FY26
- Debt to equity
- 0.14FY26
- Net profit margin
- −47,989.0%FY26
- Book value / share
- ₹5.17FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
SAMSRITA LABS quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹242 Cr | ₹214 Cr | ₹202 Cr | ₹320 Cr | ₹255 Cr | ₹247 Cr | ₹209 Cr | ₹347 Cr |
| Revenue YoY | −0.0% | −0.1% | — | +31.9% | +5.4% | +15.3% | +3.1% | +8.7% |
| Net profit | ₹12 Cr | ₹6 Cr | ₹7 Cr | ₹21 Cr | ₹19 Cr | ₹14 Cr | ₹11 Cr | ₹22 Cr |
| Net profit YoY | −31.7% | −45.8% | — | +53.5% | +49.9% | +127.5% | +55.7% | +7.0% |
| Net margin | 5.1% | 2.8% | 3.5% | 6.5% | 7.3% | 5.6% | 5.3% | 6.4% |
| EPS | ₹10.09 | ₹4.95 | ₹5.75 | ₹16.83 | ₹15.12 | ₹11.26 | ₹8.96 | ₹18.00 |
SAMSRITA LABS financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | — |
| Operating profit | −₹1 Cr | ₹2 Cr | −₹1 Cr | −₹0 Cr | −₹0 Cr | — |
| Net profit | −₹1 Cr | ₹2 Cr | −₹1 Cr | −₹0 Cr | −₹0 Cr | — |
| EPS (₹) | ₹0.00 | ₹1.00 | ₹0.00 | ₹0.00 | ₹0.00 | — |
| Cash from operations | −₹0 Cr | −₹0 Cr | ₹1 Cr | −₹0 Cr | −₹0 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹11 Cr | ₹13 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
SAMSRITA LABS shareholding pattern
| Holder | 30 Jun 2025 | 18 Jul 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 48.25% | 31.41% | 31.41% | 25.44% | 25.44% | 25.44% |
| Foreign institutions | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% |
| Domestic institutions | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 51.75% | 68.59% | 68.59% | 74.56% | 74.56% | 74.56% |
SAMSRITA LABS vs peers
The listed Pharma & Healthcare companies nearest to SAMSRITA LABS by market capitalisation.
Ask anything about SAMSRITA LABS
Pivot answers on the live chart with evidence you can check, and tests strategies against SAMSRITA's own history. Try: “Why has SAMSRITA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SAMSRITA over five years” · “Compare SAMSRITA with KKSHL on margins and valuation”
Frequently asked questions about SAMSRITA LABS
What is the market cap of SAMSRITA LABS?
SAMSRITA LABS's market capitalisation is ₹28 Cr (₹28 Cr) at the 22 Oct 2026 close, ranking 3413th among the NSE companies Pivot tracks.
What is the ROE and ROCE of SAMSRITA LABS?
Return on equity was −69.4% in FY26 and return on capital employed was −73.3% in FY26 (consolidated figures).
Is SAMSRITA LABS a debt-free company?
No. SAMSRITA LABS's debt-to-equity ratio was 0.14 in FY26, with total debt of ₹0 Cr.
What were SAMSRITA LABS's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), SAMSRITA LABS reported revenue of ₹347 Cr, +8.7% year on year, and net profit of ₹22 Cr, +7.0% year on year.
What is the shareholding pattern of SAMSRITA LABS?
As of 30 Jun 2026: promoters 25.44%, foreign institutions 0.00%, domestic institutions 0.00%, non-institutions 74.56%.
Who are SAMSRITA LABS's competitors?
The listed Pharma & Healthcare companies closest to SAMSRITA LABS by market cap are KK Shah Hospita, Panjon, Soni Medicare, Chennai Meenaks, Tejnaksh and Parmax Pharma.
Is SAMSRITA LABS a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out SAMSRITA LABS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAMSRITA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text